JAK-POT: Real-World Risk of Treatment Discontinuation Across 17 International Registers of Patients With Rheumatoid Arthritis

June 3-6, 2020; Virtual Meeting
Numerically lower probability of discontinuation with JAK inhibitors vs TNF inhibitors in adjusted analysis of 25,521 patients with rheumatoid arthritis.
Format: Microsoft PowerPoint (.ppt)
File Size: 187 KB
Released: July 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Susan Schrimpf Davis, DO Released: October 7, 2020

Expert commentary on hATTR pathobiology and the importance of early and accurate diagnosis.

Aaron Walfish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: October 1, 2020 Expired: September 30, 2021

Short CME/CE-certified video from CCO: Expert review of case studies improving evaluation and diagnosis of patients with hATTR.

Jonathan Mazurek, MD Aaron Walfish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: September 21, 2020 Expired: September 20, 2021

Slides from CCO: Experts discuss case studies for improving diagnosis and evaluation of Hereditary Transthyretin Amyloidosis (hATTR).

Jonathan Mazurek, MD Aaron Walfish, MD Released: September 21, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue